Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

Paller CJ, Antonarakis ES.

Hum Vaccin Immunother. 2012 Apr;8(4):509-19. doi: 10.4161/hv.18860. Epub 2012 Apr 1. Review.

PMID:
22336881
2.

Pharmaco-economic aspects of sipuleucel-T.

Simoens S.

Hum Vaccin Immunother. 2012 Apr;8(4):506-8. doi: 10.4161/hv.18334. Epub 2012 Feb 16. Review.

PMID:
22336882
3.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Gardner TA, Elzey BD, Hahn NM.

Hum Vaccin Immunother. 2012 Apr;8(4):534-9. doi: 10.4161/hv.19795. Review.

PMID:
22832254
4.

An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.

Wesley JD, Whitmore J, Trager J, Sheikh N.

Hum Vaccin Immunother. 2012 Apr;8(4):520-7. doi: 10.4161/hv.18769. Epub 2012 Feb 28. Review.

PMID:
22370520
5.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
6.

Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM.

Expert Rev Anticancer Ther. 2014 Jan;14(1):51-61. doi: 10.1586/14737140.2014.848065. Review.

PMID:
24224900
7.

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.

Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.

Expert Rev Vaccines. 2011 Jun;10(6):743-53. doi: 10.1586/erv.11.70. Review.

8.

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.

Can J Urol. 2015 Dec;22(6):8048-55. Review.

PMID:
26688132
9.

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

Wei XX, Fong L, Small EJ.

Expert Rev Vaccines. 2015;14(12):1529-41. doi: 10.1586/14760584.2015.1099437. Epub 2015 Oct 21. Review.

PMID:
26488270
10.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

11.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

12.

Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.

Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.

Can J Urol. 2014 Apr;21(2 Supp 1):48-56. Review.

13.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

14.

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.

Mulders PF, De Santis M, Powles T, Fizazi K.

Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30. Review.

15.

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.

Holko P, Kawalec P.

Expert Rev Anticancer Ther. 2014 Jan;14(1):63-73. doi: 10.1586/14737140.2014.856270. Review.

PMID:
24224852
16.

Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

Lü C, Williams AK, Chalasani V, Martínez CH, Chin J.

Expert Opin Biol Ther. 2011 Jan;11(1):99-108. doi: 10.1517/14712598.2011.538677. Epub 2010 Nov 17. Review.

PMID:
21080858
17.

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

Antonarakis ES, Drake CG.

Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0. Review.

18.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
19.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
20.

Integration of immunotherapy into the management of advanced prostate cancer.

Kantoff P, Higano CS.

Urol Oncol. 2012 Sep-Oct;30(5 Suppl):S41-7. doi: 10.1016/j.urolonc.2012.06.002. Review.

PMID:
23040162

Supplemental Content

Support Center